Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Research

Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation

Authors: Tengda Li, Maowen Huang, Ning Sun, Xiaohui Hua, Ruifan Chen, Qipeng Xie, Shirui Huang, Mengxiang Du, Yazhen Zhao, Qianqian Lin, Jiheng Xu, Xiaoyun Han, Yunping Zhao, Zhongxian Tian, Yu Zhang, Wei Chen, Xian Shen, Chuanshu Huang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Background

Phosphatase and tensin homolog deleted on chromosome ten (PTEN) serves as a powerful tumor suppressor, and has been found to be downregulated in human bladder cancer (BC) tissues. Despite this observation, the mechanisms contributing to PTEN’s downregulation have remained elusive.

Methods

We established targeted genes’ knockdown or overexpressed cell lines to explore the mechanism how it drove the malignant transformation of urothelial cells or promoted anchorageindependent growth of human basal muscle invasive BC (BMIBC) cells. The mice model was used to validate the conclusion in vivo. The important findings were also extended to human studies.

Results

In this study, we discovered that mice exposed to N-butyl-N-(4-hydroxybu-tyl)nitrosamine (BBN), a specific bladder chemical carcinogen, exhibited primary BMIBC accompanied by a pronounced reduction in PTEN protein expression in vivo. Utilizing a lncRNA deep sequencing high-throughput platform, along with gain- and loss-of-function analyses, we identified small nucleolar RNA host gene 1 (SNHG1) as a critical lncRNA that might drive the formation of primary BMIBCs in BBN-treated mice. Cell culture results further demonstrated that BBN exposure significantly induced SNHG1 in normal human bladder urothelial cell UROtsa. Notably, the ectopic expression of SNHG1 alone was sufficient to induce malignant transformation in human urothelial cells, while SNHG1 knockdown effectively inhibited anchorage-independent growth of human BMIBCs. Our detailed investigation revealed that SNHG1 overexpression led to PTEN protein degradation through its direct interaction with HUR. This interaction reduced HUR binding to ubiquitin-specific peptidase 8 (USP8) mRNA, causing degradation of USP8 mRNA and a subsequent decrease in USP8 protein expression. The downregulation of USP8, in turn, increased PTEN polyubiquitination and degradation, culminating in cell malignant transformation and BMIBC anchorageindependent growth. In vivo studies confirmed the downregulation of PTEN and USP8, as well as their positive correlations in both BBN-treated mouse bladder urothelium and tumor tissues of bladder cancer in nude mice.

Conclusions

Our findings, for the first time, demonstrate that overexpressed SNHG1 competes with USP8 for binding to HUR. This competition attenuates USP8 mRNA stability and protein expression, leading to PTEN protein degradation, consequently, this process drives urothelial cell malignant transformation and fosters BMIBC growth and primary BMIBC formation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol. 2022;23:650–8.PubMedCrossRef Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol. 2022;23:650–8.PubMedCrossRef
3.
go back to reference Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128:2085–97.PubMedCrossRef Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128:2085–97.PubMedCrossRef
4.
go back to reference Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, Netto G, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2021;79:364–71.PubMedCrossRef Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, Netto G, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2021;79:364–71.PubMedCrossRef
5.
go back to reference Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.PubMedCrossRef Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.PubMedCrossRef
7.
go back to reference Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19:547–62.PubMedCrossRef Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19:547–62.PubMedCrossRef
8.
go back to reference Kang SY, Kim DG, Kim KM. BAT26 only microsatellite instability with high tumor mutation burden-a rare entity associated with PTEN protein loss and high PD-L1 expression. Int J Mol Sci. 2022;23(18):10730.PubMedPubMedCentralCrossRef Kang SY, Kim DG, Kim KM. BAT26 only microsatellite instability with high tumor mutation burden-a rare entity associated with PTEN protein loss and high PD-L1 expression. Int J Mol Sci. 2022;23(18):10730.PubMedPubMedCentralCrossRef
9.
go back to reference Fortin J, Bassi C, Ramachandran P, Li WY, Tian R, Zarrabi I, Hill G, et al. Concerted roles of PTEN and ATM in controlling hematopoietic stem cell fitness and dormancy. J Clin Invest. 2021;131(5):e131698.PubMedPubMedCentralCrossRef Fortin J, Bassi C, Ramachandran P, Li WY, Tian R, Zarrabi I, Hill G, et al. Concerted roles of PTEN and ATM in controlling hematopoietic stem cell fitness and dormancy. J Clin Invest. 2021;131(5):e131698.PubMedPubMedCentralCrossRef
10.
go back to reference Bai D, Wu Y, Deol P, Nobumori Y, Zhou Q, Sladek FM, Liu X. Palmitic acid negatively regulates tumor suppressor PTEN through T366 phosphorylation and protein degradation. Cancer Lett. 2021;496:127–33.PubMedCrossRef Bai D, Wu Y, Deol P, Nobumori Y, Zhou Q, Sladek FM, Liu X. Palmitic acid negatively regulates tumor suppressor PTEN through T366 phosphorylation and protein degradation. Cancer Lett. 2021;496:127–33.PubMedCrossRef
11.
go back to reference Zhang Z, Xu H, Ji J, Shi X, Lyu J, Zhu Y, Yu H, et al. Heterogeneity of PTEN and PPAR-γ in cancer and their prognostic application to bladder cancer. Exp Ther Med. 2019;18:3177–83.PubMedPubMedCentral Zhang Z, Xu H, Ji J, Shi X, Lyu J, Zhu Y, Yu H, et al. Heterogeneity of PTEN and PPAR-γ in cancer and their prognostic application to bladder cancer. Exp Ther Med. 2019;18:3177–83.PubMedPubMedCentral
12.
go back to reference Almaimani RA, Aslam A, Ahmad J, El-Readi MZ, El-Boshy ME, Abdelghany AH, Idris S, et al. In vivo and in vitro enhanced tumoricidal effects of metformin, active vitamin D3, and 5-fluorouracil triple therapy against colon cancer by modulating the PI3K/Akt/PTEN/mTOR network. Cancers (Basel). 2022;14(6):1538.PubMedCrossRef Almaimani RA, Aslam A, Ahmad J, El-Readi MZ, El-Boshy ME, Abdelghany AH, Idris S, et al. In vivo and in vitro enhanced tumoricidal effects of metformin, active vitamin D3, and 5-fluorouracil triple therapy against colon cancer by modulating the PI3K/Akt/PTEN/mTOR network. Cancers (Basel). 2022;14(6):1538.PubMedCrossRef
13.
go back to reference Chen Z, Thomas SN, Bolduc DM, Jiang X, Zhang X, Wolberger C, Cole PA. Enzymatic analysis of PTEN Ubiquitylation by WWP2 and NEDD4-1 E3 ligases. Biochemistry. 2016;55:3658–66.PubMedCrossRef Chen Z, Thomas SN, Bolduc DM, Jiang X, Zhang X, Wolberger C, Cole PA. Enzymatic analysis of PTEN Ubiquitylation by WWP2 and NEDD4-1 E3 ligases. Biochemistry. 2016;55:3658–66.PubMedCrossRef
14.
go back to reference Li Z, Hong S, Liu Z. LncRNA LINC00641 predicts prognosis and inhibits bladder cancer progression through miR-197-3p/KLF10/PTEN/PI3K/AKT cascade. Biochem Biophys Res Commun. 2018;503:1825–9.PubMedCrossRef Li Z, Hong S, Liu Z. LncRNA LINC00641 predicts prognosis and inhibits bladder cancer progression through miR-197-3p/KLF10/PTEN/PI3K/AKT cascade. Biochem Biophys Res Commun. 2018;503:1825–9.PubMedCrossRef
15.
go back to reference Zhan CH, Ding DS, Zhang W, Wang HL, Mao ZY, Liu GJ. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling. Bioengineered. 2022;13:8478–89.PubMedPubMedCentralCrossRef Zhan CH, Ding DS, Zhang W, Wang HL, Mao ZY, Liu GJ. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling. Bioengineered. 2022;13:8478–89.PubMedPubMedCentralCrossRef
16.
go back to reference Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 2018;17:141.PubMedPubMedCentralCrossRef Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 2018;17:141.PubMedPubMedCentralCrossRef
17.
go back to reference Xiao B, Huang Z, Zhou R, Zhang J, Yu B. The prognostic value of expression of the long noncoding RNA (lncRNA) small nucleolar RNA Host Gene 1 (SNHG1) in patients with solid malignant tumors: a systematic review and meta-analysis. Med Sci Monit. 2018;24:5462–72.PubMedPubMedCentralCrossRef Xiao B, Huang Z, Zhou R, Zhang J, Yu B. The prognostic value of expression of the long noncoding RNA (lncRNA) small nucleolar RNA Host Gene 1 (SNHG1) in patients with solid malignant tumors: a systematic review and meta-analysis. Med Sci Monit. 2018;24:5462–72.PubMedPubMedCentralCrossRef
18.
go back to reference Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018;118:24–30.PubMedCrossRef Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018;118:24–30.PubMedCrossRef
19.
go back to reference Wang H, Wang G, Gao Y, Zhao C, Li X, Zhang F, Jiang C, et al. Lnc-SNHG1 activates the TGFBR2/SMAD3 and RAB11A/Wnt/beta-catenin pathway by sponging MiR-302/372/373/520 in invasive pituitary tumors. Cell Physiol Biochem. 2018;48:1291–303.PubMedCrossRef Wang H, Wang G, Gao Y, Zhao C, Li X, Zhang F, Jiang C, et al. Lnc-SNHG1 activates the TGFBR2/SMAD3 and RAB11A/Wnt/beta-catenin pathway by sponging MiR-302/372/373/520 in invasive pituitary tumors. Cell Physiol Biochem. 2018;48:1291–303.PubMedCrossRef
20.
go back to reference Xu J, Yang R, Hua X, Huang M, Tian Z, Li J, Lam HY, et al. lncRNA SNHG1 promotes basal bladder cancer invasion via Interaction with PP2A catalytic subunit and induction of autophagy. Mol Ther Nucleic Acids. 2020;21:354–66.PubMedPubMedCentralCrossRef Xu J, Yang R, Hua X, Huang M, Tian Z, Li J, Lam HY, et al. lncRNA SNHG1 promotes basal bladder cancer invasion via Interaction with PP2A catalytic subunit and induction of autophagy. Mol Ther Nucleic Acids. 2020;21:354–66.PubMedPubMedCentralCrossRef
21.
go back to reference Xu J, Hua X, Jin H, Zhu J, Li Y, Li J, Huang C. NFkappaB2 p52 stabilizes rhogdibeta mRNA by inhibiting AUF1 protein degradation via a miR-145/Sp1/USP8-dependent axis. Mol Carcinog. 2019;58:777–93.PubMedCrossRef Xu J, Hua X, Jin H, Zhu J, Li Y, Li J, Huang C. NFkappaB2 p52 stabilizes rhogdibeta mRNA by inhibiting AUF1 protein degradation via a miR-145/Sp1/USP8-dependent axis. Mol Carcinog. 2019;58:777–93.PubMedCrossRef
22.
go back to reference Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, Huang H, et al. XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta mRNA stability. Int J Cancer. 2018;142:2040–55.PubMedCrossRef Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, Huang H, et al. XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta mRNA stability. Int J Cancer. 2018;142:2040–55.PubMedCrossRef
23.
go back to reference Huang C, Liao X, Jin H, Xie F, Zheng F, Li J, Zhou C, et al. MEG3, as a competing endogenous RNA, binds with miR-27a to promote PHLPP2 protein translation and impairs bladder cancer invasion. Mol Ther Nucleic Acids. 2019;16:51–62.PubMedPubMedCentralCrossRef Huang C, Liao X, Jin H, Xie F, Zheng F, Li J, Zhou C, et al. MEG3, as a competing endogenous RNA, binds with miR-27a to promote PHLPP2 protein translation and impairs bladder cancer invasion. Mol Ther Nucleic Acids. 2019;16:51–62.PubMedPubMedCentralCrossRef
24.
go back to reference Wang Y, Xu J, Gao G, Li J, Huang H, Jin H, Zhu J, et al. Tumor-suppressor NFκB2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494. Oncogene. 2016;35:4080–90.PubMedCrossRef Wang Y, Xu J, Gao G, Li J, Huang H, Jin H, Zhu J, et al. Tumor-suppressor NFκB2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494. Oncogene. 2016;35:4080–90.PubMedCrossRef
25.
go back to reference Jin H, Xu J, Guo X, Huang H, Li J, Peng M, Zhu J, et al. XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63alpha protein translation and promoting transformation of bladder epithelial cells. Oncotarget. 2016;7:56540–57.PubMedPubMedCentralCrossRef Jin H, Xu J, Guo X, Huang H, Li J, Peng M, Zhu J, et al. XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63alpha protein translation and promoting transformation of bladder epithelial cells. Oncotarget. 2016;7:56540–57.PubMedPubMedCentralCrossRef
26.
go back to reference Zhu J, Li Y, Chen C, Ma J, Sun W, Tian Z, Li J, et al. NF-kappaB p65 overexpression promotes bladder cancer cell migration via FBW7-mediated degradation of RhoGDIalpha protein. Neoplasia. 2017;19:672–83.PubMedPubMedCentralCrossRef Zhu J, Li Y, Chen C, Ma J, Sun W, Tian Z, Li J, et al. NF-kappaB p65 overexpression promotes bladder cancer cell migration via FBW7-mediated degradation of RhoGDIalpha protein. Neoplasia. 2017;19:672–83.PubMedPubMedCentralCrossRef
27.
go back to reference Huang S, Hua X, Kuang M, Zhu J, Mu H, Tian Z, Zheng X, et al. miR-190 promotes malignant transformation and progression of human urothelial cells through CDKN1B/p27 inhibition. Cancer Cell Int. 2021;21:241.PubMedPubMedCentralCrossRef Huang S, Hua X, Kuang M, Zhu J, Mu H, Tian Z, Zheng X, et al. miR-190 promotes malignant transformation and progression of human urothelial cells through CDKN1B/p27 inhibition. Cancer Cell Int. 2021;21:241.PubMedPubMedCentralCrossRef
28.
go back to reference Zhu J, Tian Z, Li Y, Hua X, Zhang D, Li J, Jin H, et al. ATG7 promotes bladder cancer invasion via autophagy-mediated increased ARHGDIB mRNA stability. Adv Sci (Weinh). 2019;6:1801927.PubMedCrossRef Zhu J, Tian Z, Li Y, Hua X, Zhang D, Li J, Jin H, et al. ATG7 promotes bladder cancer invasion via autophagy-mediated increased ARHGDIB mRNA stability. Adv Sci (Weinh). 2019;6:1801927.PubMedCrossRef
29.
go back to reference Fang Y, Cao Z, Hou Q, Ma C, Yao C, Li J, Wu XR, et al. Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells. Mol Cancer Ther. 2013;12:1492–503.PubMedPubMedCentralCrossRef Fang Y, Cao Z, Hou Q, Ma C, Yao C, Li J, Wu XR, et al. Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells. Mol Cancer Ther. 2013;12:1492–503.PubMedPubMedCentralCrossRef
30.
go back to reference Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, Liao X, et al. Isorhapontigenin (ISO) inhibits invasive bladder cancer formation in vivo and human bladder cancer invasion in vitro by targeting STAT1/FOXO1 axis. Cancer Prev Res (Phila). 2016;9:567–80.PubMedCrossRef Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, Liao X, et al. Isorhapontigenin (ISO) inhibits invasive bladder cancer formation in vivo and human bladder cancer invasion in vitro by targeting STAT1/FOXO1 axis. Cancer Prev Res (Phila). 2016;9:567–80.PubMedCrossRef
31.
go back to reference Jin H, Xu J, Guo X, Huang H, Li J, Peng M, Zhu J, et al. XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63α protein translation and promoting transformation of bladder epithelial cells. Oncotarget. 2016;7:56540–57.PubMedPubMedCentralCrossRef Jin H, Xu J, Guo X, Huang H, Li J, Peng M, Zhu J, et al. XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63α protein translation and promoting transformation of bladder epithelial cells. Oncotarget. 2016;7:56540–57.PubMedPubMedCentralCrossRef
32.
go back to reference Somji S, Bathula CS, Zhou XD, Sens MA, Sens DA, Garrett SH. Transformation of human urothelial cells (UROtsa) by as and cd induces the expression of keratin 6a. Environ Health Perspect. 2008;116:434–40.PubMedCrossRef Somji S, Bathula CS, Zhou XD, Sens MA, Sens DA, Garrett SH. Transformation of human urothelial cells (UROtsa) by as and cd induces the expression of keratin 6a. Environ Health Perspect. 2008;116:434–40.PubMedCrossRef
33.
go back to reference Xu J, Wang Y, Hua X, Xu J, Tian Z, Jin H, Li J, et al. Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFkappaB2 (p100). Oncotarget. 2016;7:34112–30.PubMedPubMedCentralCrossRef Xu J, Wang Y, Hua X, Xu J, Tian Z, Jin H, Li J, et al. Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFkappaB2 (p100). Oncotarget. 2016;7:34112–30.PubMedPubMedCentralCrossRef
34.
go back to reference Zhou C, Huang C, Wang J, Huang H, Li J, Xie Q, Liu Y, et al. LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1alpha translation. Oncogene. 2017;36:3878–89.PubMedPubMedCentralCrossRef Zhou C, Huang C, Wang J, Huang H, Li J, Xie Q, Liu Y, et al. LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1alpha translation. Oncogene. 2017;36:3878–89.PubMedPubMedCentralCrossRef
35.
go back to reference Lin MG, Hong YK, Zhang Y, Lin BB, He XJ. Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN. Eur Rev Med Pharmacol Sci. 2018;22:3370–7.PubMed Lin MG, Hong YK, Zhang Y, Lin BB, He XJ. Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN. Eur Rev Med Pharmacol Sci. 2018;22:3370–7.PubMed
36.
38.
go back to reference Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol. 2000;11:141–8.PubMedCrossRef Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol. 2000;11:141–8.PubMedCrossRef
39.
40.
go back to reference Leestemaker Y, Ovaa H. Tools to investigate the ubiquitin proteasome system. Drug Discov Today Technol. 2017;26:25–31.PubMedCrossRef Leestemaker Y, Ovaa H. Tools to investigate the ubiquitin proteasome system. Drug Discov Today Technol. 2017;26:25–31.PubMedCrossRef
41.
go back to reference Ventii KH, Wilkinson KD. Protein partners of deubiquitinating enzymes. Biochem J. 2008;414:161–75.PubMedCrossRef Ventii KH, Wilkinson KD. Protein partners of deubiquitinating enzymes. Biochem J. 2008;414:161–75.PubMedCrossRef
42.
go back to reference Sun F, Sun Y, Zhu J, Wang X, Ji C, Zhang J, Chen S, et al. Mesenchymal stem cells-derived small extracellular vesicles alleviate diabetic retinopathy by delivering NEDD4. Stem Cell Res Ther. 2022;13:293.PubMedPubMedCentralCrossRef Sun F, Sun Y, Zhu J, Wang X, Ji C, Zhang J, Chen S, et al. Mesenchymal stem cells-derived small extracellular vesicles alleviate diabetic retinopathy by delivering NEDD4. Stem Cell Res Ther. 2022;13:293.PubMedPubMedCentralCrossRef
43.
go back to reference Seufert L, Benzing T, Ignarski M, Müller RU. RNA-binding proteins and their role in kidney disease. Nat Rev Nephrol. 2022;18:153–70.PubMedCrossRef Seufert L, Benzing T, Ignarski M, Müller RU. RNA-binding proteins and their role in kidney disease. Nat Rev Nephrol. 2022;18:153–70.PubMedCrossRef
44.
go back to reference Schieweck R, Ninkovic J, Kiebler MA. RNA-binding proteins balance brain function in health and disease. Physiol Rev. 2021;101:1309–70.PubMedCrossRef Schieweck R, Ninkovic J, Kiebler MA. RNA-binding proteins balance brain function in health and disease. Physiol Rev. 2021;101:1309–70.PubMedCrossRef
46.
go back to reference Garcia-Maurino SM, Rivero-Rodriguez F, Velazquez-Cruz A, Hernandez-Vellisca M, Diaz-Quintana A, De la Rosa MA, Diaz-Moreno I. RNA binding protein regulation and cross-talk in the control of AU-rich mRNA fate. Front Mol Biosci. 2017;4:71.PubMedPubMedCentralCrossRef Garcia-Maurino SM, Rivero-Rodriguez F, Velazquez-Cruz A, Hernandez-Vellisca M, Diaz-Quintana A, De la Rosa MA, Diaz-Moreno I. RNA binding protein regulation and cross-talk in the control of AU-rich mRNA fate. Front Mol Biosci. 2017;4:71.PubMedPubMedCentralCrossRef
48.
49.
go back to reference Hua X, Huang M, Deng X, Xu J, Luo Y, Xie Q, Xu J, et al. The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein. Cell Death Differ. 2020;27:632645.CrossRef Hua X, Huang M, Deng X, Xu J, Luo Y, Xie Q, Xu J, et al. The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein. Cell Death Differ. 2020;27:632645.CrossRef
50.
go back to reference Zhang Y, Mao Q, Xia Q, Cheng J, Huang Z, Li Y, Chen P, et al. Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers. J Hematol Oncol. 2021;14:169.PubMedPubMedCentralCrossRef Zhang Y, Mao Q, Xia Q, Cheng J, Huang Z, Li Y, Chen P, et al. Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers. J Hematol Oncol. 2021;14:169.PubMedPubMedCentralCrossRef
51.
53.
go back to reference Ribeiro DM, Zanzoni A, Cipriano A, Delli Ponti R, Spinelli L, Ballarino M, Bozzoni I, et al. Protein complex scaffolding predicted as a prevalent function of long non-coding RNAs. Nucleic Acids Res. 2018;46:917–28.PubMedCrossRef Ribeiro DM, Zanzoni A, Cipriano A, Delli Ponti R, Spinelli L, Ballarino M, Bozzoni I, et al. Protein complex scaffolding predicted as a prevalent function of long non-coding RNAs. Nucleic Acids Res. 2018;46:917–28.PubMedCrossRef
55.
go back to reference Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:d92-7.PubMedCrossRef Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:d92-7.PubMedCrossRef
56.
57.
go back to reference Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022.PubMedCrossRef Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022.PubMedCrossRef
58.
go back to reference Kaur J, Choi W, Geynisman DM, Plimack ER, Ghatalia P. Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol. 2021;13:17588359211045858.PubMedPubMedCentral Kaur J, Choi W, Geynisman DM, Plimack ER, Ghatalia P. Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol. 2021;13:17588359211045858.PubMedPubMedCentral
59.
go back to reference Ghandour R, Singla N, Lotan Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer. Trends Cancer. 2019;5:426–39.PubMedCrossRef Ghandour R, Singla N, Lotan Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer. Trends Cancer. 2019;5:426–39.PubMedCrossRef
60.
go back to reference Steinberg GD, Trump DL, Cummings KB. Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am. 1992;19:735–46.PubMedCrossRef Steinberg GD, Trump DL, Cummings KB. Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am. 1992;19:735–46.PubMedCrossRef
61.
go back to reference Sun X, Wang Z, Yuan W. Down-regulated long non-coding RNA SNHG1 inhibits tumor genesis of colorectal carcinoma. Cancer Biomark. 2017;20:67–73.PubMedCrossRef Sun X, Wang Z, Yuan W. Down-regulated long non-coding RNA SNHG1 inhibits tumor genesis of colorectal carcinoma. Cancer Biomark. 2017;20:67–73.PubMedCrossRef
62.
go back to reference Zhu Y, Li B, Liu Z, Jiang L, Wang G, Lv M, Li D. Up-regulation of lncRNA SNHG1 indicates poor prognosis and promotes cell proliferation and metastasis of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Oncotarget. 2017;8:111715–27.PubMedPubMedCentralCrossRef Zhu Y, Li B, Liu Z, Jiang L, Wang G, Lv M, Li D. Up-regulation of lncRNA SNHG1 indicates poor prognosis and promotes cell proliferation and metastasis of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Oncotarget. 2017;8:111715–27.PubMedPubMedCentralCrossRef
63.
go back to reference Zhao Y, Qin ZS, Feng Y, Tang XJ, Zhang T, Yang L. Long non-coding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) promote cell proliferation in colorectal cancer by affecting P53. Eur Rev Med Pharmacol Sci. 2018;22:976–84.PubMed Zhao Y, Qin ZS, Feng Y, Tang XJ, Zhang T, Yang L. Long non-coding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) promote cell proliferation in colorectal cancer by affecting P53. Eur Rev Med Pharmacol Sci. 2018;22:976–84.PubMed
64.
go back to reference Tian T, Qiu R, Qiu X. SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer. Oncotarget. 2018;9:2128–39.PubMedCrossRef Tian T, Qiu R, Qiu X. SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer. Oncotarget. 2018;9:2128–39.PubMedCrossRef
65.
go back to reference Zhang H, Zhou D, Ying M, Chen M, Chen P, Chen Z, Zhang F. Expression of long non-coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) exacerbates hepatocellular carcinoma through suppressing miR-195. Med Sci Monit. 2016;22:4820–9.PubMedPubMedCentralCrossRef Zhang H, Zhou D, Ying M, Chen M, Chen P, Chen Z, Zhang F. Expression of long non-coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) exacerbates hepatocellular carcinoma through suppressing miR-195. Med Sci Monit. 2016;22:4820–9.PubMedPubMedCentralCrossRef
66.
go back to reference Li J, Zhang Z, Xiong L, Guo C, Jiang T, Zeng L, Li G, et al. SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2017;487:146–52.PubMedCrossRef Li J, Zhang Z, Xiong L, Guo C, Jiang T, Zeng L, Li G, et al. SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2017;487:146–52.PubMedCrossRef
67.
go back to reference Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187–98.PubMedCrossRef Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187–98.PubMedCrossRef
68.
go back to reference Ma X, Zhou J, Liu J, Wu G, Yu Y, Zhu H, Liu J. LncRNA ANCR promotes proliferation and radiation resistance of nasopharyngeal carcinoma by inhibiting PTEN expression. Onco Targets Ther. 2018;11:8399–408.PubMedPubMedCentralCrossRef Ma X, Zhou J, Liu J, Wu G, Yu Y, Zhu H, Liu J. LncRNA ANCR promotes proliferation and radiation resistance of nasopharyngeal carcinoma by inhibiting PTEN expression. Onco Targets Ther. 2018;11:8399–408.PubMedPubMedCentralCrossRef
69.
go back to reference Ge F, Li Y, Yuan T, Wu Y, He Q, Yang B, Zhu H. Deubiquitinating enzymes: Promising targets for drug resistance. Drug Discov Today. 2022;27:2603–13.PubMedCrossRef Ge F, Li Y, Yuan T, Wu Y, He Q, Yang B, Zhu H. Deubiquitinating enzymes: Promising targets for drug resistance. Drug Discov Today. 2022;27:2603–13.PubMedCrossRef
70.
72.
go back to reference Ohanna M, Biber P, Deckert M. Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis. Cancers (Basel). 2022;14(14):3371.PubMedCrossRef Ohanna M, Biber P, Deckert M. Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis. Cancers (Basel). 2022;14(14):3371.PubMedCrossRef
73.
go back to reference Liang W, Fang J, Zhou S, Hu W, Yang Z, Li Z, Dai L, et al. The role of ubiquitin-specific peptidases in glioma progression. Biomed Pharmacother. 2022;146:112585.PubMedCrossRef Liang W, Fang J, Zhou S, Hu W, Yang Z, Li Z, Dai L, et al. The role of ubiquitin-specific peptidases in glioma progression. Biomed Pharmacother. 2022;146:112585.PubMedCrossRef
75.
go back to reference Xie F, Zhou X, Li H, Su P, Liu S, Li R, Zou J, et al. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII. Embo j. 2022;41:e108791.PubMedPubMedCentralCrossRef Xie F, Zhou X, Li H, Su P, Liu S, Li R, Zou J, et al. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII. Embo j. 2022;41:e108791.PubMedPubMedCentralCrossRef
Metadata
Title
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation
Authors
Tengda Li
Maowen Huang
Ning Sun
Xiaohui Hua
Ruifan Chen
Qipeng Xie
Shirui Huang
Mengxiang Du
Yazhen Zhao
Qianqian Lin
Jiheng Xu
Xiaoyun Han
Yunping Zhao
Zhongxian Tian
Yu Zhang
Wei Chen
Xian Shen
Chuanshu Huang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-02966-4

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine